Keio University · Medicine
Professor Yoshinori Katsumata's research lab focuses on cardiovascular protection mechanisms, particularly the role of lipid mediators such as prostaglandin D2 and its metabolites in ischemia-reperfusion injury. The lab investigates how glucocorticoids exert cardioprotective effects through the upregulation of lipocalin-type prostaglandin D synthase and downstream signaling pathways. A key research direction involves understanding the gene regulatory networks activated by PGD2 and its derivatives, with translational applications in acute myocardial infarction and interventional cardiology. The lab also explores clinical interventions such as controlled hypotension during percutaneous coronary intervention to promote left ventricular reverse remodeling after STEMI.
Figures are computed from collected data and may differ slightly.
We recently demonstrated that glucocorticoids markedly upregulate the expression of cyclooxygenase-2 in cardiomyocytes and protect hearts from ischemia-reperfusion (I/R) injury by activating lipocalin-type prostaglandin D (PGD) synthase (L-PGDS)-derived PGD(2) biosynthesis. We examined a downstream mechanism of cardioprotection elicited by PGD(2) biosynthesis. Acute PGD(2) treatment did not protect hearts against I/R injury. We then speculated that PGD(2) and its metabolite 15-deoxy-Δ12,14-PGJ(2
The first clinical study has shown that HI during PCI is feasible and safe and may also promote LV reverse remodeling at 6 months after STEMI. The study was not powered to test efficacy and a further large-scale trial is warranted. (Clinical trials registration: UMIN00006825).
Open papers in the app to read, cite, and organize with AI.
